Investment Firm Maintains ''Buy'' Rating For Major Biotech Company

In the dynamic world of biotechnology, Novavax, Inc. (NASDAQ: NVAX) remains a company to watch, despite recent adjustments in its price target by HC Wainwright & Co. The investment firm recently maintained its "Buy" rating on Novavax but lowered the price target from its previous estimate to $19. This development has stirred discussions among investors and market analysts alike, prompting a closer look at Novavax's prospects. $Novavax(NVAX.US)$